The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

The human immune system displays substantial variation between individuals, leading to
differences in susceptibility to autoimmune disease. We present single-cell RNA sequencing …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …

Several non-redundant features of the tumour microenvironment facilitate
immunosuppression and limit anticancer immune responses. These include physical …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …